American Regent vs. Apotex: Trace Elements Drug Patent Case Consolidated in New Jersey
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | American Regent, Inc. v. Apotex Inc. |
| Case Number | 2:24-cv-02268 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | March 2024 – July 2024 114 days |
| Outcome | Consolidated (Lead Case: 24-1022) |
| Patents at Issue | |
| Accused Products | Apotex Trace Elements Injection Products |
Case Overview
The Parties
⚖️ Plaintiff
U.S.-based pharmaceutical company with a focused portfolio in injectable drug products, including specialty and critical-care formulations. ARI holds commercial rights to Multrys® and Tralement®.
🛡️ Defendant
Canadian generic pharmaceutical manufacturer, one of North America’s largest producers of generic drugs. Its U.S. commercial arm, Apotex Corp., distributes generic formulations.
The Patent at Issue
This landmark case involved U.S. Patent No. US11786548B2 (application number US17/365695), covering technology in the pharmaceutical formulation space — specifically relating to trace elements injection products. Trace elements injections containing zinc, copper, manganese, and selenium (the four-element formulation designated as “4*”) are used in parenteral nutrition protocols for hospitalized patients, making this a clinically significant and commercially valuable category.
Developing a similar drug formulation?
Check if your pharmaceutical product might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
This case was closed via consolidation rather than through trial, summary judgment, or settlement. The court’s order consolidated Civil Action Nos. 24-1022, 24-1030, 24-1169, and 24-2268 into a single proceeding maintained under Case No. 24-1022. All future filings and proceedings for the Apotex defendants are now governed within that consolidated matter. No damages were awarded, no injunctive relief was entered, and no claim construction rulings issued in this specific docket prior to consolidation.
Key Legal Issues
The court’s order granted a joint request by all parties, finding “good cause” to merge the related actions. This procedural alignment is significant: it suggests that the underlying patent claims, accused products, and legal theories across all four actions share sufficient commonality to warrant unified management. In multi-defendant pharmaceutical patent litigation, consolidation eliminates the risk of inconsistent claim constructions across parallel proceedings, reduces duplicative discovery, and streamlines expert testimony on technical issues — particularly critical when the patent at issue involves complex pharmaceutical formulation chemistry. This setup allows for a single Markman hearing to produce a unified claim construction binding on all defendants, a key strategic benefit.
Freedom to Operate (FTO) Analysis in Pharmaceutical Injectables
This case highlights critical IP risks in pharmaceutical formulation. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patents and their claim scope in the trace elements space
- See which companies are active in injectable drug formulations
- Understand claim construction implications from consolidation
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your drug formulation or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Area
Injectable drug formulations (e.g., trace elements)
1 Patent (Consolidated)
US11786548B2 is central to 4 cases
Hatch-Waxman Implications
Monitor 30-month stays and FDA timelines
✅ Key Takeaways
Multi-defendant consolidation in pharmaceutical patent litigation streamlines Markman proceedings but requires careful co-defendant coordination on invalidity and non-infringement positions.
Search related case law →New Jersey District Court remains a premier venue for pharmaceutical patent actions; strategic venue selection here reflects established pharmaceutical litigation infrastructure.
Explore precedents →The ‘548 patent (US11786548B2) and its claim scope will be central to the consolidated proceeding — monitor docket 24-1022 for claim construction developments.
Track patent status →Frequently Asked Questions
The case involves U.S. Patent No. US11786548B2 (application no. US17/365695), covering technology related to trace elements injection 4*, USP formulations.
The case was not resolved on the merits. It was consolidated with three related ARI actions — Case Nos. 24-1022, 24-1030, and 24-1169 — into a single lead proceeding under Civil Action No. 24-1022 in the District of New Jersey.
A unified claim construction ruling in the consolidated proceeding will define the enforceable scope of the ‘548 patent against all named generic defendants simultaneously, making the Markman hearing in Case No. 24-1022 a critical watch point for the industry.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Docket — Case No. 2:24-cv-02268
- USPTO Patent Center — US11786548B2
- Cornell Legal Information Institute — Hatch-Waxman Act Overview
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.